DOCSLIB.ORG

ADULT IMMUNISATION 2Nd Edition

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ADULT IMMUNISATION 2Nd Edition Malaysian Society of Infectious Diseases and Chemotherapy GUIDELINES FOR ADULT IMMUNISATION 2nd Edition 1 Quick Guide3 19-21 22-26 27-49 50-59 60-64 ≥65 yrs yrs yrs yrs yrs yrs Influenza* 1 dose annually Tetanus, diphtheria, Substitute 1-time dose of Tdap for Td booster; pertussis (Td/Tdap)* then boost with Td every 10 yrs Varicella* 2 doses Human papillomavirus 3 doses (HPV) Female* Human papillomavirus 3 3 (HPV) Male* doses doses Zoster* 1 dose Measles, mumps, 1 or 2 doses rubella (MMR)* Pneumococcal 1 dose conjugate (PCV)* Pneumococcal 1 or 2 doses 1 dose polysaccharide (PPV)* Meningococcal* 1 or more doses Hepatitis A* 2 doses Hepatitis B* 3 doses Haemophilus 1 or 3 doses influenzaetype b (Hib)* For all persons in this category who meet the age requirements and who lack documentation of vaccination or have no evidence of previous infection; zoster vaccine recommended regardless of prior episode of zoster Recommended if some other risk factor is present (eg, on the basis of medical, occupational, lifestyle, or other) No recommendation *Please refer to relevant section for more details 2 Malaysian Society of Infectious Diseases and Chemotherapy GUIDELINES FOR ADULT IMMUNISATION 2nd Edition Supported by an educational grant from 3 Malaysian Society of Infectious Diseases and Chemotherapy ISBN 978-967-13054-0-9 First Edition Published December 2003 Second Edition Published April 2014, Revised October 2016 Copyright © Malaysian Society of Infectious Diseases and Chemotherapy (MSIDC) 2014 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording and/or otherwise, without the prior written permission from the publisher. Applications for such permission should be addressed to Malaysian Society of Infectious Diseases and Chemotherapy. Published by: Malaysian Society of Infectious Diseases and Chemotherapy c/o Department of Medical Microbiology, Faculty of Medicine, University Kebangsaan Malaysia, Hospital Univeristy Kebangsaan Malaysia, Jalan Yaacob Latif, Bandar Tun Razak, Cheras, 56000, Kuala Lumpur, Malaysia. Printed by: Print Wise Enterprise Sdn Bhd 4 Expert Panel Chair Prof Dr Victor K E Lim Vice President (Education) and Professor of Pathology International Medical University (IMU) Kuala Lumpur Members Assoc Prof Dr Ariza Adnan Dr Timothy William Deputy Dean (Academic & Student) & State Infectious Disease Consultant Consultant Clinical Microbiologist Queen Elizabeth Hospital Faculty of Medicine Sabah Universiti Teknologi MARA Selangor Prof Dr Yasmin A Malik Consultant Microbiologist (Virology) & Dato Dr Chang Kian Meng Head Department of Pre-Clinical Sciences Head & Consultant Haematologist Faculty of Medicine & Health Sciences Department of Haematology Universiti Tunku Abdul Rahman (UTAR) Hospital Ampang Selangor Selangor Prof Dr Zamberi Sekawi Prof Datin Dr Ilina Isahak Deputy Dean & Professor of Medical Microbiology Medical Professor Faculty of Medicine & Health Sciences Faculty of Medicine & Health Sciences Universiti Putra Malaysia (UPM) Universiti Sains Islam Malaysia (USIM) Selangor Kuala Lumpur Assoc Prof Dr Zetti Zainol Rashid Mrs Noraisyah Mohd Sani Senior Lecturer & Clinical Microbiologist Senior Principal Assistant Director Department of Medical Microbiology & Immunology Pharmacovigilance Section Faculty of Medicine Centre for Post Registration of Products Universiti Kebangsaan Malaysia Medical Centre National Pharmaceutical Control Bureau Kuala Lumpur Selangor External reviewers Dr Nor Liza Ariffin Senior Lecturer Dr Rohani binti Jahis Monash University Malaysia Head of the Vaccine Prevention of Disease/Food & Consultant Infectious Diseases Physician Water Borne Diseases Sime Darby Medical Center Disease Control Division, Ministry of Health Malaysia Selangor Wilayah Persekutuan Dr Suresh Kumar Chidambaram Ms Sameerah Shaikh Abdul Rahman Consultant Infectious Diseases Physician Deputy Director Hospital Sungai Buloh Centre for Post Registration of Products Selangor National Pharmaceutical Control Bureau Selangor 5 Contents Introduction 10 General Advice on Immunisation 12 Vaccine-preventable Diseases • Cholera 30 • Diphtheria, Tetanus, Pertussis (DTP) 34 • Haemophilus influenzae Type b Infections 51 • Hepatitis A 55 • Hepatitis B 60 • Human Papillomavirus Infections 67 • Influenza 77 • Japanese Encephalitis 84 • Measles, Mumps, Rubella (MMR) 90 • Meningococcal Disease 102 • Pneumococcal Disease 107 6 • Poliomyelitis 114 • Rabies 118 • Typhoid 126 • Varicella 132 • Yellow Fever 138 • Zoster 141 Passive Immunisation 144 Upcoming Vaccines 148 Special Groups 156 7 Abbreviations ADR adverse drug reactions HBIG hepatitis B immunoglobulin AEFI adverse event following HBsAg hepatitis B surface antigen immunisation HBV hepatitis B virus AIDS acquired immunodeficiency HCW healthcare worker syndrome HDCV human diploid cell vaccine (rabies) anti-HBc antibody to hepatitis B core HepA hepatitis A vaccine antigen HepB hepatitis B vaccine anti-HBe antibody to hepatitis B e antigen HHE hypotonic-hyporesponsive episode anti-HBs antibody to hepatitis B surface antigen Hib Haemophilus influenzae type b AOM acute otitis media Hib-MenCCV Haemophilus influenzae type b-Meningococcal C conjugate AVA anthrax vaccine adsorbed vaccine BCG bacille Calmette-Guérin HIV human immunodeficiency virus CCID50 cell culture infectious dose 50% HPV human papillomavirus CCVs cell culture vaccines HPV2 bivalent HPV vaccine CI confidence interval HPV4 quadrivalent HPV vaccine CIN cervical intraepithelial neoplasia HRIG human rabies immunoglobulin CRS congenital rubella syndrome HSCT haematopoietic stem cell transplant CSF cerebrospinal fluid HZ herpes zoster DNA deoxyribonucleic acid HZV herpes zoster (Shingles) vaccine DT diphtheria-tetanus (vaccine for use in (formerly called ZOS) children) ID intradermal DTaP diphtheria and tetanus toxoids and IgA/G/M immunoglobulin A/G/M acellular pertussis vaccine (pediatric formulation replaced DTP) IIV inactivated influenza vaccine (formerly called TIV) EIA enzyme immunoassay IM intramuscular eIPV enhanced inactivated polio vaccine IPD invasive pneumococcal disease ELISA enzyme-linked immunosorbent assay IPV inactivated poliomyelitis vaccine FHA filamentous haemagglutinin IS intussusception FIM fimbriae (pertussis) ITP idiopathic thrombocytopenia purpura GBS Guillain-Barré syndrome IU international units GP general practitioner IV intravenous GVHD graft-versus-host disease JE Japanese encephalitis HAV hepatitis A virus JE-MB inactivated, mouse brain-derived Japanese encephalitis vaccine HBcAg hepatitis B core antigen LAIV live, attenuated influenza vaccine HBeAg hepatitis B e antigen (nasal spray) 8 LT-ETEC heat-labile toxin producing PRP polyribosylribitol phosphate enterotoxigenic Escherichia coli PRP-OMP PRP conjugated to MCV measles antigen-containing vaccines the outer membrane protein MCV4 meningococcal conjugate vaccine (of Neisseria meningitidis) (quadravalent) PRP-T PRP conjugated to tetanus toxoid MenACWY-CRM meningococcal PT pertussis toxoid conjugate vaccine, quadrivalent PVRV purified vero cell-based vaccine MenACWY-D meningococcal conjugate RCT randomised controlled trial vaccine, quadrivalent RIG rabies immunoglobulin MenC meningitis C RNA ribonucleic acid MMR measles-mumps-rubella SC subcutaneous MMRV measles-mumps-rubella-varicella SCID severe combined immunodeficiency NHIG normal human immunoglobulin SIDS sudden infant death syndrome NIP National Immunisation Program SOT solid organ transplant NPCB National Pharmaceutical Control SSPE subacute sclerosing Bureau panencephalitis NTHi non-typeable Haemophilus TB tuberculosis influenzae TCID50 tissue culture infectious dose 50% OMP outer membrane protein Td tetanus & diphtheria vaccine (adult/ OPV oral poliomyelitis vaccine adolescent formulation) PCECV purified chick embryo cell vaccine Tdap tetanus, diphtheria & acellular (rabies) pertussis vaccine (adult/adolescent PCR polymerase chain reaction formulation) PCV pneumococcal conjugate vaccine TGA Therapeutic Goods Administration PCV10 pneumococcal conjugate vaccine TIG tetanus immunoglobulin (10 valent) TST tuberculin skin test PCV13 pneumococcal conjugate vaccine TT tetanus toxoid (13 valent) Ty21a live oral typhoid vaccine PCV7 pneumococcal conjugate vaccine (7 valent) VAR varicella vaccine PEP post-exposure prophylaxis VLP virus-like particle pH1N1 pandemic influenza A(H1N1) VNAb (rabies) virus neutralising antibody pdm09 VPD vaccine-preventable disease PHN post-herpetic neuralgia VV varicella vaccine PI product information VZV varicella-zoster virus PPV23 pneumococcal polysaccharide WA Western Australia vaccine (23-valent) WHO World Health Organization PRN pertactin ZIG zoster immunoglobulin 9 Introduction mmunisation against infectious diseases has been primarily directed towards infants, children and adolescents and has become a routine Ipractice in paediatrics. In many countries, including Malaysia, adult immunisation is not commonly practised. There is a lack of awareness of the benefits of immunisation for adults, even though there is considerable morbidity and mortality within this age group due to vaccine-preventable diseases. Vaccine-preventable diseases are still commonly encountered in Malaysia. The Ministry of Health Malaysia data for 2011, showed that the incidence rates for measles, hepatitis B and pertussis were 5.42, 4.32, 0.86 per 100,000 population respectively. In Singapore, it has been reported that the proportion of influenza associated deaths
Load more

Recommended publications
  • Vermont Rabies Control Resource Manual 2018
    Vermont Rabies Control Resource Manual 2018 Health Surveillance HealthVermont.gov Table of Contents Introduction ............................................................................................................... 3 Section 1: Rabies in Vermont ........................................................................................5 A. Vermont Rabies Control Overview B. Vermont Rabies Epidemiology Section 2: Vermont-Specific Rules and Statutes .......................................................... 13 A. Reportable and Communicable Diseases Rule B. 20 VSA Chapter 193: Domestic Pet or Wolf-Hybrid Control C. Animal Rabies Vaccination Rules Section 3: National Guidelines .................................................................................... 50 A. Compendium of Animal Rabies Prevention and Control, 2016 B. Human Rabies Prevention—United States, 2008 C. Use of a Reduced (4-Dose) Vaccine Schedule for Postexposure Prophylaxis to Prevent Human Rabies, 2010 Section 4: Vermont Recommendations ....................................................................... 111 A. School Animal Policy Guide Section 5: Rabies Exposure Protocols ......................................................................... 116 A. Human Rabies Exposure Management by Animal Type B. Management of Potential Human Exposures to Rabies C. Rabies Exposure Management for Bat-related Incidents D. Management of Potential Pet Exposures to Rabies Section 6: Rabies Testing and Reporting Forms ..........................................................
    [Show full text]
  • ADULT IMMUNISATION 2Nd Edition
    Malaysian Society of Infectious Diseases and Chemotherapy GUIDELINES FOR ADULT IMMUNISATION 2nd Edition 1 Quick Guide3 19-21 22-26 27-49 50-59 60-64 ≥65 yrs yrs yrs yrs yrs yrs Influenza* 1 dose annually Tetanus, diphtheria, Substitute 1-time dose of Tdap for Td booster; pertussis (Td/Tdap)* then boost with Td every 10 yrs Varicella* 2 doses Human papillomavirus 3 doses (HPV) Female* Human papillomavirus 3 3 (HPV) Male* doses doses Zoster* 1 dose Measles, mumps, 1 or 2 doses rubella (MMR)* Pneumococcal 1 dose conjugate (PCV)* Pneumococcal 1 or 2 doses 1 dose polysaccharide (PPV)* Meningococcal* 1 or more doses Hepatitis A* 2 doses Hepatitis B* 3 doses Haemophilus 1 or 3 doses influenzaetype b (Hib)* For all persons in this category who meet the age requirements and who lack documentation of vaccination or have no evidence of previous infection; zoster vaccine recommended regardless of prior episode of zoster Recommended if some other risk factor is present (eg, on the basis of medical, occupational, lifestyle, or other) No recommendation *Please refer to relevant section for more details 2 Malaysian Society of Infectious Diseases and Chemotherapy GUIDELINES FOR ADULT IMMUNISATION 2nd Edition Supported by an educational grant from 3 Malaysian Society of Infectious Diseases and Chemotherapy ISBN 978-967-13054-0-9 First Edition Published December 2003 Second Edition Published April 2014, Revised November 2014 Copyright © Malaysian Society of Infectious Diseases and Chemotherapy (MSIDC) 2014 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording and/or otherwise, without the prior written permission from the publisher.
    [Show full text]
  • Evaluation of Prophylactic Efficacy of Human Anti-Rabies
    EVALUATION OF PROPHYLACTIC EFFICACY OF HUMAN ANTI-RABIES MONOCLONAL ANTIBODIES IN A MOUSE MODEL by CHAKRAVARTHY CHENNAREDDY (Under the direction of Zhen Fu) ABSTRACT Rabies post exposure prophylaxis (PEP) includes administration of both vaccine and anti-rabies immunoglobulin. Rabies immunoglobulins are expensive and available in limited quantities. There is an inherent variability in quality and specificity between batches of immunoglobulin preparations and possibility of contamination with known or unknown pathogens. To provide a cost-effective and safe replacement for currently used human rabies immunoglobulin (HRIG) human anti-rabies monoclonal antibodies (huMAbs) were developed. The present study evaluated the overall prophylactic efficacy of SO57 and SOJB MAbs individually, in a mouse model when used in combination with rabies vaccine and compared with conventional HRIG. When the protective effect of antibodies was examined in mice challenged with CVS-N2C virus, a dose-dependent survivorship response was observed in animals treated with antibodies and no animal survived in the control group. At the highest dose of antibody given 80% survivorship was recorded for SO57 and SOJB antibodies where as only 50% survived with HRIG. Serum half-lives were found to be approximately 16 days for SO57 (IgG1); 11 days for SOJB (IgG3) and 8 days for HRIG (polyclonal). Furthermore, we investigated the potential interference of antibodies on vaccine mediated- immunity. When compared to the control group which was given only vaccine shots, the groups of animals given both antibody and vaccine developed lower virus neutralizing antibody (VNA) titers. The VNA titers appear to be a function of dose of antibody given and serum half-life of each antibody.
    [Show full text]
  • Rabies Immune Globulin (Human
    Individuals using assistive technology may not be able to fully access the information contained in this file. For assistance, please send an e-mail to: [email protected] and include 508 Accommodation and the title of the document in the subject line of your e-mail. HIGHLIGHTS OF PRESCRIBING INFORMATION Single-dose vials containing 2 mL or 10 mL ready-to-use solution with a These highlights do not include all the information needed to use potency of 150 IU/mL.(3) ___________________ ____________________ KEDRAB safely and effectively. See full prescribing information for CONTRAINDICATIONS KEDRAB. ® None. (4) KEDRAB Rabies Immune Globulin (Human) solution for wound ----------------------WARNINGS AND PRECAUTIONS----------------------- infiltration and intramuscular injection • Do not give KEDRAB to persons who have completed rabies pre- or post- Initial U.S. Approval: 2017 exposure prophylaxis because it can interfere with the anamnestic response __________________ _________________ to the rabies vaccine. (5.1) RECENT MAJOR CHANGES • Hypersensitivity reactions, including anaphylaxis, may occur with Indications and Usage KEDRAB. IgA deficient patients with antibodies against IgA are at greater Dosage and Administration (2) MM/2021 risk. Have epinephrine available immediately to treat any acute severe __________________ _________________ INDICATIONS AND USAGE hypersensitivity reactions. (5.2). KEDRAB is a human rabies immune globulin (HRIG) indicated for passive, • Interference with live attenuated virus vaccines. (5.5, 7) transient post-exposure prophylaxis of rabies infection to persons of all ages • KEDRAB is made from human plasma, and may carry a risk of when given immediately after contact with a rabid or possibly rabid animal. transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob KEDRAB should be administered concurrently with a full course of rabies disease (vCJD) agent, and theoretically, the Creutzfeldt-Jakob disease vaccine (1).
    [Show full text]
  • WHO Guide for Rabies Pre and Post Exposure Prophylaxis in Humans Updated 2013
    WHO Guide for Rabies Pre and Post Exposure Prophylaxis in Humans Updated 2013 Health Statistics and Informatics General considerations in rabies Post-Exposure Prophylaxis (PEP) • WHO recommends the use of purified rabies vaccines prepared on cell culture or embryonated eggs (referred to as CCEEVs) for PEP; • These vaccines must comply with WHO criteria for potency, innocuity and have been assessed satisfactorily in humans in well-designed field trials; • WHO strongly recommends discontinuation of production and use of nerve-tissue vaccines and their replacement with CCEEVs. Health StatisticsUpdated and 2013 Informatics Top 10 general considerations in rabies PEP 1. Wounds must be immediately washed/flushed for 15 minutes and disinfected; 2. Rabies PEP is an emergency and as a general rule must not be delayed or deferred. Vaccine and in severe exposure immunoglobulin therapy must be instituted as soon as possible. Health StatisticsUpdated and 2013 Informatics Top 10 general considerations in rabies PEP 3. PEP does not have contraindications if purified rabies immunoglobulin and vaccine are used. Pregnancy and infancy are no contraindications to PEP; 4. PEP must be applied using vaccine regimens and routes of administration that have been proven to be safe and effective; 5. If rabies immunoglobulin is not available on first visit its use can be delayed by a maximum of 7 days from date of first vaccine injection. Updated 2013 Health Statistics and Informatics Top 10 general considerations in rabies PEP 6. Initiation of PEP should not await the results of laboratory diagnosis or be delayed by dog observation when rabies is suspected 7. When suspect rabid animal contacts (excluding bats) occur in an area free of carnivore rabies and where there is adequate rabies surveillance, PEP may not be required.
    [Show full text]
  • Dostupnost Antiinfektiv V České Republice
    aktuálně ročník 27 | číslo 5/2017 LÉKY A PRÁVO Dostupnost antiinfektiv v České republice MVDr. Veronika Valdová Arete‑Zoe, LLC Souhrn Valdová V. Dostupnost antiinfektiv v České republice. Remedia 2017; 27: 509–513. na Seznamu nepostradatelných léčiv Světové zdravotnické organizace figuruje 119 antiinfektiv, z nichž v České republice není registrováno 29. Dalších 10 léčiv je registrováno, ale neobchodováno. Dostupnost antibiotik a dalších nezbytných léčiv má přímý dopad na klinickou praxi. Příkladem je aktuali- zovaný postup pro léčbu sepse a septického šoku, který doporučuje deeskalaci a zacílení na identifikovaný patogen ihned po jeho identifikaci z důvodu snížení zátěže pro organismus pacienta. aktualizované léčebné postupy je nutno brát v úvahu při sestavování národních seznamů nepostradatelných léčiv. Z nepostradatelných tuberkulostatik a antivirotik chybějí v ČR některé fixní kombinace určené pro první linii léčby tuberkulózy a HIV/aIDS. Padělky léčivých přípravků a nedoléčené infekce jsou hlavními příčinami vzniku multirezistentních kmenů původce tuberkulózy. Z hyperimunních sér v ČR chybí sérum proti záškrtu. Vakcíny se potýkají s celosvětovým nedostatkem v důsledku délky a náročnosti výroby. Klíčová slova: antiinfektiva – nepostradatelná léčiva – dostupnost léčiv – nedostatek léčiv – tuberkulóza – HIV/aIDS – sepse. Summary Valdova V. Availability of antiinfectives in the Czech Republic. Remedia 2017; 27: 509–513. the World Health Organization (WHO) lists 119 antiinfectives on the list of essential medicines. Of these, 29 are not registered in the Czech Republic, and another 10 are registered but not marketed. availability of antimicrobials and other essential medicines directly affects clinical practice. One such example is the newly revised guidelines for the treatment of sepsis and septic shock, which recommends deescalation of antibiotic treatment and targeting the causative pathogen immediately after its identification to minimize toxicity to the patient’s metabolism.
    [Show full text]
  • The Selection and Use of Essential Medicines
    This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization WHO Technical Report Series 933 THE SELECTION AND USE OF ESSENTIAL MEDICINES Report of the WHO Expert Committee, 2005 (including the 14th Model List of Essential Medicines) World Health Organization Geneva 2006 i WHO Library Cataloguing-in-Publication Data WHO Expert Committee on the Selection and Use of Essential Medicines (14th : 2005: Geneva, Switzerland) The selection and use of essential medicines : report of the WHO Expert Committee, 2005 : (including the 14th model list of essential medicines). (WHO technical report series ; 933) 1.Essential drugs — standards 2.Formularies — standards 3.Drug information services — organization and administration 4.Drug utilization 5. Pharmaceutical preparations — classification 6.Guidelines I.Title II.Title: 14th model list of essential medicines III.Series. ISBN 92 4 120933 X (LC/NLM classification: QV 55) ISSN 0512-3054 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 2476; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publica- tions — whether for sale or for noncommercial distribution — should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
    [Show full text]
  • Kedrab. Reliable Coverage for Every Rabies Exposure
    Indicated for post-exposure prophylaxis (PEP) of rabies infection KEDRAB. RELIABLE COVERAGE FOR EVERY RABIES EXPOSURE Eliminate the HRIG Dosing and Administration Guesswork Ready-to-use human rabies immune globulin (HRIG) solution1 May be stored at room temperature not exceeding 25°C (77°F) for up to one month. Use within one month; do not return to refrigeration1 150 IU/mL potency, the standard for nearly 50 years2 No need for dilution with dextrose1 No need for new HRIG protocols or staff trainings 2-mL vial/300 IU 10-mL vial/1500 IU INDICATIONS AND USAGE KEDRABTM (Rabies Immune Globulin [Human]) is a human rabies immunoglobulin (HRIG) indicated for passive, transient post-exposure prophylaxis (PEP) of rabies infection, when given immediately after contact with a rabid or possibly rabid animal. KEDRAB should be administered concurrently with a full course of rabies vaccine. • Additional doses of KEDRAB should not be administered once vaccine treatment has been initiated, since this may interfere with the immune response to the rabies vaccine. • KEDRAB should not be administered to patients with a history of a complete pre-exposure or post-exposure vaccination regimen and confirmed adequate rabies antibody titer. SELECTED IMPORTANT SAFETY INFORMATION • Patients who can document previous complete rabies pre-exposure prophylaxis or complete post-exposure prophylaxis should only receive a booster rabies vaccine without KEDRAB, because KEDRAB may interfere with the anamnestic response to the vaccine (ACIP). Please see page 6 for full Important Safety Information and full Prescribing Information on pages 7-19. Visit KEDRAB.com or call 1-855-353-7466 to order KEDRAB today.
    [Show full text]
  • Frequently Asked Questions on Rabies © World Health Organization 2013 All Rights Reserved
    Rabies is one of the oldest diseases known to humans, and is a serious public threat in many countries in South-East Asia. There is still no treatment available once a patient develops the symptoms of rabies. These FAQs are an attempt to provide accepted and evidence-based answers to common questions about the disease. If a person is bitten by an animal: Wounds should be washed and flushed immediately with soap and water for 10–15 minutes. If soap is not available, flush with water alone. This is the most effective first-aid treatment against rabies. Wounds should be cleaned thoroughly with 70% alcohol/ethanol or povidone-iodine, if available. As soon as possible, take the person to a health-care facility for further treatment. To download this booklet and other FAQs about infectious diseases, Frequently Asked Questions please visit: http://www.searo.who.int/about/administration_structure/cds/en/ on Rabies index.html World Health House Indraprastha Estate Mahatma Gandhi Marg New Delhi-110002, India SEA-CD-278 SEA-CD-278 FREQUENTLY ASKED QUESTIONS ON RABIES © World Health Organization 2013 All rights reserved. Requests for publications, or for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – can be obtained from Bookshop, World Health Organization, Regional Office for South-East Asia, Indraprastha Estate, Mahatma Gandhi Marg, New Delhi 110 002, India (fax: +91 11 23370197; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
    [Show full text]
  • ACIP Meeting Minutes
    DEPARTMENT OF HEALTH AND HUMAN SERVICES CENTERS FOR DISEASE CONTROL AND PREVENTION Advisory Committee on Immunization Practices June 27-28, 2007 Atlanta, Georgia Record of the Proceedings C O N T E N T S Day 1, June 27, 2007 WELCOME AND INTRODUCTION Dr. Abramson......................................……………………………………………. 1 Dr. Pickering.....................................……………………………………………… 1 Dr. Abramson......................................……………………………………………. 2 HEPATITIS A VACCINE Introduction: Dr. Lieu............................................................................................... 3 Postexposure and Travel Prophylaxis: Dr. Novak.................................................... 4 Vote...........................................................................................................................10 Travel Recommendations: Dr. Novak...................................................................... 11 Vote.......................................................................................................................... 11 VFC Vote: Dr. Calugar............................................................................................ 12 VACCINE FINANCING Underinsured Children: Dr. Lee............................................................................... 13 AMA/AAP Immunization Congress: Dr. Orenstein................................................. 16 NVAC Financing Working Group: Dr. Birkhead..................................................... 18 PROPOSED REVISIONS TO THE ADULT IMMUNIZATION SCHEDULE
    [Show full text]
  • Human Rabies Immune Globulin (HRIG) Administration Considerations—The ART of HRIG
    AUTUMN 2019 • ISSUE #10 YOUR SOURCE FOR RABIES AWARENESS AND EDUCATION Human Rabies Immune Globulin (HRIG) Administration Considerations—The ART of HRIG Quiz 1. How much of the HRIG dose should you 2. If there is remaining volume of HRIG, administer into and around the wound? where should be administered? o As much as possible o Deltoid same side as vaccine o Approximately half o Deltoid opposite side as vaccine If you weren’t entirely certain of the answers, you are not alone! When it comes to HRIG administration, factors such as selection of wound-site dosage and anatomical site for the remaining HRIG can vary according to situations and it is not always straightforward for HCPs working in emergency rooms (ERs). In general, though, as we will discuss in this article, it is recommended that as much HRIG as possible should be administered into and around the wound, and if there is any remaining HRIG it should be administered collaterally to the side of vaccination.1 As you know, rabies is almost always fatal after a patient becomes symptomatic. Appropriate postexposure prophylaxis (PEP) is critical to prevent central nervous system infection and subsequent death. The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) recommend that humans who are exposed to the rabies virus should receive PEP care consisting of wound cleansing, infiltration of HRIG, and rabies vaccination.1 CDC guidelines recommend that HRIG be administered at a dose of 20 IU/kg body weight, with the full dose infiltrated into and around the wound(s), if anatomically feasible.
    [Show full text]
  • Walter A. Orenstein, MD, Dsc (Hon)
    CURRICULUM VITAE Revised: July 2018 1. Name: Walter A. Orenstein, MD, DSc (Hon) 2. Office Address: Emory Vaccine Center Telephone: 404-712-2466 Fax: 404-712-2557 Emory University Mailstop: 1370/004/1AD 1462 Clifton Rd., Room 446, Dental Bldg Atlanta, GA 30322 3. E-mail Address: [email protected] 4. Citizenship: United States 5. Current Titles and Affiliations: 1. Primary appointments: 7/01/11 – Present Professor of Medicine – Infectious Diseases, Emory University 2. Joint and secondary appointments: 7/01/11 – Present Professor – Hubert Department of Global Health, Rollins School of Public Health 7/01/11 – Present Professor – Pediatrics, Infectious Diseases 6/01/13 – Present Professor - Epidemiology 3. Administrative appointments: 7/01/11 – Present Director, Emory Program for Vaccine Policy and Development 7/01/11 – Present Associate Director, Emory Vaccine Center 4. Affiliate Professor 4/20/10 – Present Department of Global Health, University of Washington, Seattle, WA 6. Previous Academic and Professional Appointments 3/15/04 – 10/6/08 Professor of Medicine – Infectious Diseases, Emory University School of Medicine 3/15/04 – 10/6/08 Professor – Hubert Department of Global Health, Rollins School of Public Health, Emory University 3/15/04 –10/6/08 Professor – Pediatrics, Infectious Diseases, Emory University School of Medicine 10/7/08 – 7/1/11 Deputy Director for Immunization Programs, Vaccine Delivery Team, Global Health Program, Bill and Melinda Gates Foundation 7. Previous Administrative and/or Clinical Appointments: a. Clinical appointments: 4/1/1985 – 8/31/92 Clinical Associate Professor, Department of Community Health, Emory University School of Medicine 9/1/1992 – 5/31/94 Clinical Associate Professor, Community Health and Rollins School of Public Health, Emory University 6/1/1994 – 3/15/04 Adjunct Clinical Professor, Department of International Health, Rollins School of Public Health, Emory University 6/3/2004 – 10/6/08 Director, Strategic Planning – The Hope Clinic, Emory University 6/1/2004 – 10/6/08 Courtesy, Emory Healthcare (Consultant) a.
    [Show full text]